RVU120 (investigational agent for MF)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-16 — RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis: Trial-early: A clinical trial will evaluate efficacy, safety, PK, and PD of RVU120 as monotherapy or combined with ruxolitinib in adults with intermediate- or high-risk primary or secondary myelofibrosis — first protocol-level MF evaluation of RVU120, no efficacy data yet. (novelty: 3)
Open questions
Related
Contributing findings
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
16-sep-2026
novelty 3
per-area 4
introduces